SCHEDULE: Adage Capital Discloses 5.29% Stake in Praxis Medicines
Beneficial Ownership Report
Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, reported a 5.29% beneficial ownership stake in Praxis Precision Medicines, Inc. as of October 31, 2025.
Summary
- Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross collectively reported beneficial ownership of 1,305,175 shares of Common Stock in Praxis Precision Medicines, Inc.
- This represents 5.29% of the company's outstanding Common Stock.
- The percentage is calculated based on 24,693,005 shares of Common Stock outstanding, which includes shares from a recent offering and the full exercise of underwriters' over-allotment option.
- The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
- This is Amendment No. 3 to the Schedule 13G filing.
Sentiment
Score: 6
Explanation: The filing indicates a significant institutional investor, Adage Capital Management, L.P., holds a 5.29% stake in Praxis Precision Medicines, Inc. While a Schedule 13G is a routine disclosure, the presence of a notable institutional holder can be interpreted as a positive signal of investor confidence, though it provides no direct information on the company's operational or financial performance.
Positives
- Institutional investor Adage Capital Management, L.P. holds a significant 5.29% stake, indicating confidence or strategic interest in Praxis Precision Medicines, Inc.
Negatives
- NA
Risks
- NA
Future Outlook
NA
Industry Context
This filing indicates continued institutional investor interest in the biotechnology or pharmaceutical sector, specifically in Praxis Precision Medicines, Inc. The disclosure of a significant stake by a prominent investment manager like Adage Capital Management can be viewed as a vote of confidence in the company's prospects within its industry.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder, which can influence market perception and potentially share price.
- Company Management: Awareness of a significant institutional investor may influence strategic decisions or communication.
Key Dates
| Date | Description |
|---|---|
| 2025-10-20 | Company's Prospectus filed pursuant to Rule 424(b)(5) and Current Report on Form 8-K filed with the SEC, reporting 24,693,005 shares outstanding after an offering and over-allotment option exercise. |
| 2025-10-31 | Date of event which requires filing of this statement (beneficial ownership calculation date). |
| 2025-11-03 | Signature date for Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross. |
Keywords
Praxis Precision Medicines, Adage Capital Management, Robert Atchinson, Phillip Gross, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.